Medexus Pharmaceuticals Inc. MDP.TO

MDP.TO Company Overview

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the commercialization and development of specialty therapeutics in the areas of hematology-oncology, rheumatology, autoimmune disease, allergy, and rare diseases. The company operates primarily in the pharmaceutical and biotechnology industries, with a business model centered on licensing, acquiring, and commercializing prescription medicines in North America. Medexus generates revenue primarily through sales of marketed pharmaceutical products and through strategic licensing arrangements tied to proprietary and in-licensed therapies.

The company’s principal revenue drivers include products such as IXINITY for hemophilia B, Rupall for allergy treatment, Metoject and Rasuvo for methotrexate-based therapies, and Gleolan for fluorescence-guided neurosurgery. Medexus has evolved through a series of acquisitions and licensing transactions since its formation in 2008, including the merger of Pediapharm Inc. and Medexus Inc. in 2018. The company has positioned itself as a specialty pharmaceutical platform focused on niche therapeutic markets with relatively limited competition, leveraging targeted commercialization capabilities across Canada and the United States.